Codexis, Inc. CDXS R2K

Q: What is the current share price of Codexis, Inc. (CDXS)?

As of 2026-07-14 21:23 PDT, Codexis, Inc. (CDXS) trades at $2.13 on NasdaqGS. Its 52-week range is $0.98 to $3.33.

Q: What is the market capitalisation of CDXS?

Codexis, Inc. (CDXS) has a market capitalisation of $193.61M on NasdaqGS.

Q: What is the P/E ratio of CDXS?

CDXS trades at a trailing price-to-earnings (P/E) ratio of -6.09. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.04.

Q: What is the return on equity (ROE) of CDXS?

CDXS has a return on equity (ROE) of -68.90%. Its return on capital employed (ROCE) is -34.08%.

Q: Is CDXS a good stock to buy?

This page provides a data-driven analysis of Codexis, Inc. (CDXS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.codexis.com

Company Profile ↓

$2.13

-30.62% 1Y

Mkt Cap$193.61M

P/E-6.09

P/B5.04

52W High$3.33

52W Low$0.98

Book Value$0.48

EPS (TTM)$-0.35

Company Overview

Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.

Recent Developments

Dec 2025 Revenue of $70.39M (+18.6% YoY); net profit $-43.97M.
Trailing 12 Months Year-on-year growth — revenue +102.1%.
5-Year Trend Long-term compounding — revenue CAGR -1.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	-1.02%
1 Year:	102.10%

Stock Price Performance

1 Year:	-30.62%
6 Months:	+29.88%
3 Months:	-7.39%
1 Month:	-11.62%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 49% of range

$0.98 $3.33

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)37.13 · Neutral

Price Performance

1M-11.62%

3M-7.39%

6M+29.88%

1Y-30.62%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Revenue declined at -1.0% CAGR over 5 years.
Trading 36.0% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-6.09

Industry PE

25.41

Forward P/E

-5.76

PEG Ratio

13.53

Book Value

$0.48

Price to Book

5.04

P/S

2.79

EV/EBITDA

-10.99

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

-1.02%

Profit 5Y

Revenue (YoY)

102.10%

Earnings (YoY)

Profitability & Returns

ROCE

-34.08%

ROE

-68.90%

ROA

-12.53%

Profit Margin

-40.97%

Op Margin

-52.75%

Gross Margin

23.83%

EPS (Latest Qtr)

$-0.10

EPS (TTM)

$-0.35

Balance Sheet & Liquidity

Debt/Equity

1.69

Quick Ratio

4.93

Current Ratio

5.36

Debt

$72.90M

Total Assets

$129.37M

Current Assets

$96.82M

Working Capital

$71.50M

Ownership

Promoter Holding

7.41%

Chg in Prom Hold

FII / Inst Holding

74.40%

Chg in FII Hold

-0.00%

Financial Snapshot

Enterprise Value

$193.61M

Total Revenue (TTM)

$78.09M

EBITDA

$-20.55M

Free Cash Flow

$-8.48M

Operating Cash Flow

$-18.73M

Shares Outstanding

90.90M

Gross Margin

23.83%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	CDXS Codexis, Inc. R2K	2.13	-6.09	$193.61M	0.00%	-34.08%	-68.90%	-1.02%	-
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Jun 2013	Sep 2013	Dec 2013	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.98M	14.04M	13.54M	16.95M	15.58M	12.32M	21.91M	14.67M	14.97M	18.39M	18.03M	25.45M	36.77M	35.34M	38.41M	34.47M	12.98M	21.32M	9.28M	17.07M	7.98M	12.83M	7.54M	15.33M	8.60M	15.25M
Operating Income	-12.45M	-9.21M	-	-6.40M	-8.91M	-4.25M	-5.53M	-5.70M	5.69M	-6.98M	2.25M	1.42M	-7.48M	-6.34M	-10.04M	-4.71M	-3.84M	-2.11M	-5.24M	-6.62M	259.00K	-7.83M	-6.11M	-6.06M	-9.15M	-4.49M	1.33M	-8.39M	-2.61M	-10.64M	-23.66M	-12.63M	-32.06M	-11.89M	-22.73M	-16.56M	-20.49M	-12.86M	-18.95M	-8.04M
Net Income	-12.61M	-9.26M	-9.81M	-6.38M	-8.48M	-4.56M	-5.56M	-5.36M	5.39M	-6.97M	2.24M	1.44M	-7.46M	-6.28M	-10.23M	-4.69M	-3.73M	-1.99M	-5.14M	-6.51M	343.00K	-7.65M	-6.34M	-6.09M	-9.07M	-4.26M	2.24M	-8.36M	-2.64M	-9.99M	-22.62M	-11.52M	-34.91M	-11.51M	-22.75M	-20.64M	-20.69M	-13.27M	-19.61M	-8.70M
Diluted EPS	-	-	-	-	-	-0.12	-	-0.14	0.13	-	0.05	0.03	-	-0.13	-0.21	-	-	-0.04	-	-	0.01	-0.13	-0.11	-0.10	-0.14	-0.07	0.03	-0.13	-0.04	-0.15	-0.34	-0.17	-0.50	-0.16	-0.32	-0.29	-0.25	-0.16	-0.22	-0.10
R&D Expense	8.62M	6.83M	8.83M	4.83M	7.73M	5.04M	5.29M	5.17M	4.99M	5.69M	5.11M	5.47M	5.84M	6.35M	8.05M	7.18M	7.37M	7.92M	8.02M	8.27M	8.71M	10.97M	10.85M	12.01M	11.57M	12.83M	15.16M	19.50M	19.09M	21.82M	16.66M	17.33M	13.66M	11.25M	11.41M	11.51M	12.94M	13.78M	13.87M	11.45M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	82.91M	107.10M	123.86M	88.30M	31.92M	35.31M	41.80M	48.84M	50.02M	60.59M	68.46M	69.06M	104.75M	138.59M	70.14M	59.34M	70.39M
Operating Income	-18.37M	-7.12M	-15.91M	-30.51M	-41.15M	-19.11M	-7.77M	-8.56M	-22.97M	-11.29M	-12.55M	-23.92M	-22.70M	-34.88M	-68.07M	-58.52M	-41.74M
Net Income	-20.29M	-8.54M	-16.55M	-30.86M	-41.30M	-19.07M	-7.58M	-8.56M	-23.00M	-10.88M	-11.94M	-24.01M	-21.28M	-33.59M	-76.24M	-65.28M	-43.97M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-0.21	-0.40	-0.33	-0.51	-1.12	-0.89	-0.50
R&D Expense	54.73M	52.41M	61.05M	56.78M	31.61M	22.75M	20.67M	22.23M	29.66M	29.98M	33.87M	44.19M	55.92M	80.10M	58.88M	46.26M	52.31M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	141.30M	135.92M	99.97M	58.84M	48.12M	44.65M	35.65M	53.62M	79.28M	149.07M	221.65M	-	250.39M	136.56M	149.01M	147.80M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	162.89M	93.47M	98.77M	96.82M
Cash & Equivalents	21.90M	31.79M	72.40M	25.76M	32.00M	22.13M	26.49M	23.27M	19.24M	31.22M	53.04M	90.50M	149.12M	-	113.98M	65.12M	19.26M	50.79M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.03M	2.69M	1.80M	1.82M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31.90M	10.04M	11.92M	8.76M
Total Liabilities	-	-	-	-	-	-	-	21.77M	16.55M	29.08M	22.98M	43.56M	51.54M	-	105.60M	49.95M	82.08M	97.27M
Current Liabilities	-	-	27.48M	28.29M	16.28M	11.20M	13.73M	14.84M	12.37M	24.95M	18.11M	15.39M	24.98M	-	49.07M	35.83M	23.65M	25.32M
Long Term Debt	-	-	-	-	-	-	-	-	0	302.00K	-	-	-	-	-	-	28.91M	40.10M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43.64M	16.02M	59.90M	73.21M
Total Equity	-129.12M	-144.84M	107.36M	102.69M	78.44M	41.48M	26.31M	22.88M	19.10M	24.55M	56.31M	105.52M	170.10M	-	144.80M	86.61M	66.93M	50.53M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	65.81M	69.91M	81.85M	90.48M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-8.79M	-16.38M	-490.00K	-11.89M	-23.00M	321.00K	-433.00K	-1.86M	-8.76M	-14.09M	-12.56M	-16.46M	-14.27M	11.28M	-52.64M	-49.41M	-19.38M
Investing Cash Flow	-20.96M	-5.17M	-48.81M	16.71M	13.27M	4.65M	-1.26M	-846.00K	-983.00K	-2.77M	-3.67M	-5.75M	-21.42M	-13.58M	-4.86M	-56.98M	23.50M
Financing Cash Flow	40.00M	62.24M	2.58M	1.26M	-147.00K	-611.00K	-1.52M	-490.00K	21.65M	38.57M	53.96M	80.81M	3.77M	-575.00K	8.17M	60.52M	27.93M
Capital Expenditure	-10.70M	-6.99M	-10.74M	-2.93M	-1.18M	-302.00K	-1.20M	-888.00K	-985.00K	-2.77M	-3.73M	-3.75M	-13.83M	-8.31M	-4.42M	-4.30M	-4.47M
Free Cash Flow	-19.48M	-23.37M	-11.23M	-14.82M	-24.17M	19.00K	-1.63M	-2.75M	-9.74M	-16.86M	-16.29M	-20.21M	-28.09M	2.98M	-57.06M	-53.72M	-23.85M

Ratios (Annual)

Figures in %.

Metric	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-22.2%	-6.7%	-12.8%	-34.6%	-128.9%	-54.1%	-18.6%	-17.5%	-45.9%	-18.6%	-18.3%	-34.6%	-21.7%	-25.2%	-97.0%	-98.6%	-59.3%
Net Margin %	-24.5%	-8.0%	-13.4%	-34.9%	-129.4%	-54.0%	-18.1%	-17.5%	-46.0%	-18.0%	-17.4%	-34.8%	-20.3%	-24.2%	-108.7%	-110.0%	-62.5%
ROE %	14.0%	-8.0%	-16.1%	-39.3%	-99.6%	-72.5%	-33.1%	-44.8%	-93.7%	-19.3%	-11.3%	-14.1%	-	-23.2%	-88.0%	-97.5%	-87.0%
ROCE %	-	-6.3%	-14.8%	-36.5%	-86.4%	-55.6%	-26.1%	-36.8%	-80.1%	-18.5%	-9.4%	-12.2%	-	-17.3%	-67.6%	-46.7%	-34.1%

Shareholding Pattern

Insiders

7.41%

Institutions

74.40%

Public Float

80.35%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Aberdeen Group plc	9.55%	8.68M	$22.44M
2	Blackrock Inc.	7.73%	7.03M	$18.17M
3	Opaleye Management Inc.	7.46%	6.79M	$17.54M
4	Nantahala Capital Management, LLC	4.54%	4.12M	$10.66M
5	Millennium Management Llc	4.40%	4.00M	$10.34M
6	Telemark Asset Management, LLC	4.23%	3.85M	$9.94M
7	Vanguard Capital Management LLC	4.04%	3.67M	$9.48M
8	Ameriprise Financial, Inc.	3.74%	3.40M	$8.79M
9	UBS Group AG	2.40%	2.18M	$5.65M
10	Geode Capital Management, LLC	2.07%	1.89M	$4.87M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CDXS

Google News Mon, 11 May 2026

Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxNQTV0cUFmWTlqcndJUzRsREZSaUpqZm5JU2E4MVUyT3BNekhyMC1nb0ZKQjdtdTg0SDNkSG8xZkVrTmEtR182NDFyRnpHajFZdjRYaHVfZ2NOZmFGU2g3ak9kdTVfNkRsTlRTS01SLTliMzhsOU02dTJXSk1rWVZSX3RMU3hXZG1kUzJNVl…

Google News hu, 25 Jun 2026

CDXS Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE4xUFB3YVNTMFpVVTlpZTI5VHVpU3QzblJwQmRoWnhhMGdZU1prR3hiYS1kT25tVWxpUG1iSEh0V1ZJdlA2Rjl0Z0g4cXBWOE94TEhmUE56WlBxSVlQeWZ3VzAwb2J3UGNPQlNUR1NIRWRLWG9Bb3RMX1BB?oc=5" target="_blank">CDX…

Google News hu, 05 Mar 2026

Why Did CDXS Stock Jump 7% Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNYm9xR3pUZHRhSkxKeGl0enNwM0g2QnVBMzVMZ1IycWtodVlrcU9QQ2tCTUNiRTFJRmVBWVNoRl8wOTg2Q3MyeG54LS1rREFfZkZUc0wxejZTUFV1OU1LTzljYk1sc21va1k2T1VVNGZwZ09DN3l1VDYxbUMzU0hZU29UV3VyeDUtUTJJQU…

Google News hu, 12 Mar 2026

Codexis rises after Q4 beat, strong outlook - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE53RlR2eUVOTmNkQmNLUDJOSFF1SVZkREdxd3FLMkpnMVFLZ2Z2dkRWbkxGR01rQ1dPTzJyb2ZnTnhrbmpiNUtEZ0tLOWI2RWUzVF9PaE90RzV6Ulg2YXVIYXRRd05YczRyeG53MHMxWlFKMGpkR1hhQk5wTVdEZw?oc=5" target="_blan…

Google News hu, 07 May 2026

Codexis says it has cash through 2027 as siRNA plans advance - Stock Titan

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQSWVVY1Q3WGlnVVFudTdYNG1fMS1qUU5FN3RNdUFVR2s0dTVOeEZOdXpudFVSU0QtckloWVRnd2hhWU1zejlMSEUxcHlQX0NpSXRNcS1NWEoxM3d5WHRWNVE0ZWdjMXpJcTNhZ2Myd1dtTzczTEsxZGJBZS1aRmxLY2xYenNjdkU2aThldT…

Google News hu, 05 Mar 2026

$CDXS stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNRktjWGRwT0RKQWxpc2pzN05EZENtdzdnWHl0RFVfQ3gtQWFkUHJuaExlSm1icUFwNGwyellQb25BUHRURXF5WkcwY0RMaDJEOENheE5wU3NJZlcxbEgzbEotNnNNMzVGZWRlTnh5TktFTnlVWU41dWxFYXZ3OHVPM3F4VzI1SzBBYld3Yz…

CDXS — Frequently Asked Questions

What is the current share price of Codexis, Inc. (CDXS)?

As of 2026-07-14 21:23 PDT, Codexis, Inc. (CDXS) trades at $2.13 on NasdaqGS. Its 52-week range is $0.98 to $3.33.

What is the market capitalisation of CDXS?

Codexis, Inc. (CDXS) has a market capitalisation of $193.61M on NasdaqGS.

What is the P/E ratio of CDXS?

CDXS trades at a trailing price-to-earnings (P/E) ratio of -6.09. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 5.04.

What is the return on equity (ROE) of CDXS?

CDXS has a return on equity (ROE) of -68.90%. Its return on capital employed (ROCE) is -34.08%.

Is CDXS a good stock to buy?

This page provides a data-driven analysis of Codexis, Inc. (CDXS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Codexis, Inc. CDXS R2K

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Earnings Release: Here's Why Analysts Cut Their Codexis, Inc. (NASDAQ:CDXS) Price Target To US$6.58 - Yahoo Finance

CDXS Forecast — Price Target — Prediction for 2027 - TradingView

Why Did CDXS Stock Jump 7% Today? - Stocktwits

Codexis rises after Q4 beat, strong outlook - Seeking Alpha

Codexis says it has cash through 2027 as siRNA plans advance - Stock Titan

$CDXS stock is up 15% today. Here's what we see in our data. - Quiver Quantitative

CDXS — Frequently Asked Questions

What is the current share price of Codexis, Inc. (CDXS)?

What is the market capitalisation of CDXS?

What is the P/E ratio of CDXS?

What is the return on equity (ROE) of CDXS?

Is CDXS a good stock to buy?

Explore More